Apr 1986 Joined Sankyo Co., Ltd. Apr 2017 General Manager, Business Planning Department, ASCA Company, the Company Apr 2018 President, ASCA Company, Daiichi Sankyo Group; Executive Officer, President, ASCA Company, the Company Apr 2021 Head of Corporate Strategy and Management Unit, Daiichi Sankyo Group; Managing Executive Officer, Head of Corporate Strategy and Management Division, CFO, the Company Jun 2021 Head of Corporate Strategy and Management Unit, Daiichi Sankyo Group; Director, Managing Executive Officer, Head of Corporate Strategy and Management Division, CFO, the Company Apr 2022 Head of Corporate Strategy and Management Unit, Daiichi Sankyo Group; Director, Senior Managing Executive Officer, Head of Corporate Strategy and Management Division, CFO, the Company Apr 2023 Representative Director, President and COO, President Executive Officer, the Company Apr 2025 Representative Director, President and CEO, President Executive Officer, the Company (current)

Apr 1987 Joined Daiichi Pharmaceutical Co., Ltd. Apr 2019 General Manager, Human Resources Department, General Affairs Division, the Company Apr 2021 Executive Officer, in charge of Human Resources, General Affairs Division, the Company Apr 2023 Head of Global HR, Daiichi Sankyo Group (current); Chief Human Resources Officer (CHRO), Daiichi Sankyo Group (current); Managing Executive Officer, the Company Jun 2024 Director, Managing Executive Officer, the Company Apr 2025 Director, Senior Managing Executive Officer, the Company Apr 2026 Head of Global Corporate Affairs, Daiichi Sankyo Group (current); Chief Corporate Affairs Officer (CCAO), Daiichi Sankyo Group (current); Director, Senior Executive Officer, the Company (current)

1984 Joined Beecham Pharmaceuticals (now GlaxoSmithKline) 1990 Joined Critical Care America Inc. 1991 Joined Amgen Inc. 2012 Joined Spectrum Pharmaceuticals, Inc. May 2014 Joined Daiichi Sankyo, Inc. as Administrative & Commercial President Jun 2016 Administrative & Commercial President, Daiichi Sankyo, Inc.; President and CEO, Luitpold Pharmaceuticals, Inc. (now American Regent, Inc.) Apr 2019 President, Daiichi Sankyo US Holdings, Inc. (current); President and CEO, Daiichi Sankyo, Inc. (current); Administrative & Commercial President, Daiichi Sankyo, Inc.; President and CEO, American Regent, Inc. Apr 2021 Head of Oncology Business Unit, Daiichi Sankyo Group (current) Jun 2025 Director, the Company (current) Apr 2026 Head of Global Oncology Business, Daiichi Sankyo Group (current)

Apr 1990 Joined Suntory Ltd. Dec 2002 Transferred to Daiichi Suntory Pharma Co., Ltd. Apr 2010 Transferred to Daiichi Sankyo Co., Ltd.; seconded to Daiichi Sankyo RD Associe Co., Ltd. Apr 2020 General Manager, Clinical Development Department III, Development Division, the Company Apr 2022 Executive Officer, General Manager, Medical Affairs, Japan Business Unit, the Company Apr 2024 Special Assignment for Patient Centricity, Daiichi Sankyo Group (current); Managing Executive Officer, General Manager, Medical Affairs, Japan Business Unit, the Company Apr 2025 Head of Japan Business Unit, Daiichi Sankyo Group (current); Managing Executive Officer, Head of Japan Business Unit and Medical Affairs Division, the Company Jun 2025 Director, Managing Executive Officer, Head of Japan Business Unit and Medical Affairs Division, the Company Apr 2026 Director, Senior Executive Officer, Head of Japan Business Unit, the Company (current)

Aug 1998 Chief, Department of Internal Medicine, St. Luke's International Hospital Nov 2007 Chief, Department of Nephrology, St. Luke's International Hospital Jan 2011 Vice President and Director, QI Center, St. Luke's International Hospital Nov 2017 Professor, Department of Health Quality and Safety, Graduate School of Medicine, Gunma University Nov 2017 Director, Department of Quality and Safety Management, Gunma University Hospital Apr 2018 Special Deputy Hospital Director (Hospital Function Evaluation), Gunma University Hospital Jun 2022 Outside Director, the Company (current) Apr 2023 Professor Emeritus and Special Professor, Gunma University (current) Apr 2023 Hospital Advisor, Gunma University Hospital (current) Apr 2023 Vice President, Itabashi Chuo General Hospital, Medical Corporation Meiho-kai May 2026 Professor, Department of Medical Safety, Tokyo Women's Medical University (current) Significant concurrent positions: Professor, Department of Medical Safety, Tokyo Women's Medical University; Professor Emeritus and Special Professor, Gunma University; Hospital Advisor, Gunma University Hospital

Apr 1982 Joined Ajinomoto Co., Inc. Jul 2004 Director, Ajinomoto Frozen Foods Co., Ltd. Jun 2007 Managing Executive Officer, Ajinomoto Frozen Foods Co., Ltd. Jun 2011 Executive Officer, Ajinomoto Co., Inc. Jun 2013 Director, Managing Executive Officer, Ajinomoto Co., Inc. Aug 2013 President and Representative Director, Ajinomoto do Brasil Jun 2015 Director, President and Chief Executive Officer, Representative Director, Ajinomoto Co., Inc. Jun 2021 Director, Representative Executive Officer, President and CEO, Ajinomoto Co., Inc. Apr 2022 Director, Executive Officer, Ajinomoto Co., Inc. Jun 2022 Special Advisor, Ajinomoto Co., Inc. Jun 2023 Outside Director, the Company (current) Significant concurrent position: Outside Director, Kao Corporation

Apr 1980 Joined Nippon Telegraph and Telephone Public Corporation Jun 2014 Director, Managing Executive Officer, Head of Enterprise IT Services Company, NTT DATA Corporation Jul 2015 Director, Managing Executive Officer, NTT DATA Corporation Jun 2016 Representative Director, Executive Vice President, NTT DATA Corporation Jun 2018 Representative Director, President, NTT DATA Corporation Jul 2023 Representative Director, President, NTT DATA Group Corporation Jun 2024 Senior Advisor, NTT DATA Group Corporation (current) Jun 2024 Outside Director, the Company (current) Significant concurrent positions: Senior Advisor, NTT DATA Group Corporation; Outside Director, Mitsui Fudosan Co., Ltd.

Jul 1990 Partner, Audit Department, KPMG LLP, New York Office Jul 1994 Representative Director, KPMG Corporate Finance Co., Ltd. Apr 2002 Representative, Akihiro Watanabe Certified Public Accountant Office (current) Apr 2004 Representative Director and CEO, GCA Corporation Jan 2024 Chairman, Houlihan Lokey K.K. Jun 2025 Outside Director, the Company (current) Significant concurrent position: Outside Director, Sapporo Holdings Limited

Apr 2000 Vice President, Lehman Brothers Securities Co., Ltd. Oct 2002 Senior Vice President, Tokyo Star Bank, Ltd. Jul 2005 Director, Managing Executive Officer, SBI Capital Co., Ltd. Jun 2006 Representative Director and President, SBI Capital Solutions Co., Ltd. (now Admiral Capital Co., Ltd.) (current) Jun 2007 Director, Managing Executive Officer, SBI Holdings, Inc. Feb 2021 Representative Director, Unifinance Co., Ltd. (current) Mar 2023 Director, Green Service Co., Ltd. (current) Jun 2025 Outside Director, the Company (current) Significant concurrent positions: Representative Director and President, Admiral Capital Co., Ltd.; Outside Director, Helios Techno Holding Co., Ltd.; Outside Director, Kusuri no Aoki Holdings Co., Ltd.

1999 Joined Amgen Inc. 2008 Managing Partner, Amgen Ventures 2009 Joined Santaris Pharma (now F. Hoffmann-La Roche); Chief Business Officer 2011 Joined Amgen Inc., Biosimilars Division; Deputy General Manager Apr 2013 Joined Daiichi Sankyo, Inc.; Global Head of Business Development; Executive Vice President, Business Development, Daiichi Sankyo, Inc. Apr 2023 Head of Global Business Development, Daiichi Sankyo Group (current); Global Head of Business Development, Daiichi Sankyo, Inc. (current)

Mar 1985 Joined Sankyo Co., Ltd. Apr 2015 General Manager, Safety Management Promotion Department, Reliability Assurance Division, the Company Apr 2017 General Manager, Safety Management Division, Reliability Assurance Division, the Company Apr 2019 Head of Reliability Assurance Unit, Daiichi Sankyo Group; Executive Officer, Head of Reliability Assurance Division, the Company Apr 2022 Executive Officer, in charge of Reliability Assurance and Safety Management, the Company Apr 2023 In charge of Audit and Supervisory Board Office, the Company Jun 2023 Full-time Audit and Supervisory Board Member, the Company (current)

Apr 1988 Joined Daiichi Pharmaceutical Co., Ltd. Apr 2021 General Manager, Internal Audit Department, the Company Apr 2024 Head of Global Internal Audit, Daiichi Sankyo Group Apr 2025 In charge of Audit and Supervisory Board Office, the Company Jun 2025 Full-time Audit and Supervisory Board Member, the Company (current)

Apr 1984 Joined Fuji Bank, Ltd. (now Mizuho Bank, Ltd.) Oct 1990 Joined Tohmatsu Audit Corporation (now Tohmatsu LLC) Aug 1994 Registered as Certified Public Accountant Jul 2007 Partner, Tohmatsu Audit Corporation Aug 2020 Representative, Masako Watanabe Certified Public Accountant Office (current) Jun 2021 Outside Audit and Supervisory Board Member, the Company (current) Aug 2021 Outside Director, Sakata Seed Corporation (current) Significant concurrent position: Outside Director, Sakata Seed Corporation

Apr 1984 Joined National Police Agency Feb 2011 Superintendent General, Okinawa Prefectural Police Headquarters Jan 2014 Director General, Criminal Investigation Department, Metropolitan Police Department Aug 2015 Senior Deputy Commissioner General, Secretariat, National Police Agency Aug 2016 Superintendent General, Osaka Prefectural Police Headquarters Jan 2018 Commissioner, Security Bureau, National Police Agency Feb 2019 Ambassador Extraordinary and Plenipotentiary to Finland Jan 2022 Crisis Management Officer, Cabinet Secretariat Apr 2024 Retired as Crisis Management Officer, Cabinet Secretariat

Jan 2013 Joined Bingham Sakai Mimura Aizawa Foreign Law Joint Enterprise Apr 2015 Joined Anderson Mori & Tomotsune Foreign Law Joint Enterprise (following merger; current) Jan 2023 Partner Attorney-at-Law, Anderson Mori & Tomotsune Foreign Law Joint Enterprise (current)